Researchers from Queen Mary University of London are recruiting patients for the CLEAR Outcomes Study to evaluate the effectiveness of new cholesterol-lowering drug bempedoic acid.

As part of the trial, researchers will see if bempedoic acid can reduce the risk of heart attacks and strokes in statin-intolerant patients who are at high risk of developing cardiovascular disease.

For the CLEAR Outcomes Study, a total of 14,000 patients are being recruited from 1,000 sites located in more than 30 countries.

The participant needs to take either bempedoic acid or a placebo daily for two to five years, with regular health checks and tests over the course of the study for the monitoring of cholesterol levels and other health factors.

Queen Mary University of London William Harvey Research Institute lead researcher Dr Manish Saxena said: “Statins are effective in lowering bad cholesterol in the body and prevent heart attacks and strokes. Unfortunately, a small number of patients are unable to tolerate statins due to side effects such as muscle aches and pains.

“This new drug called bempedoic acid is well-tolerated in these patients and previous studies have shown it to be safe and efficacious in lowering bad cholesterol.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This long-term study is investigating its effect on preventing heart attacks and strokes in high-risk patients.”

Bempedoic acid is expected to be a safe alternative treatment option for lowering cholesterol in patients who do not tolerate statins.

Both statins and bempedoic acid inhibit the creation of cholesterol in the liver and reduce cholesterol.